Characteristic activation of the MAPK pathway, which involves mutations in genes such as BRAF, MAP2K1, ARAF, ERBB3, NRAS, and KRAS, provides a rationale for the use of MAPK inhibitors in pediatric patients with LCH (7). The gene discussed is KRAS; the disease is Langerhans cell histiocytosis.